ImmunomeIMNM
IMNM
About: Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
Employees: 105
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
57% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 28
28% more capital invested
Capital invested by funds: $588M [Q2] → $755M (+$167M) [Q3]
10% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 20
4.96% more ownership
Funds ownership: 81.02% [Q2] → 85.99% (+4.96%) [Q3]
2% more funds holding
Funds holding: 112 [Q2] → 114 (+2) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q2] → 2 (+0) [Q3]
83% less call options, than puts
Call options by funds: $4.72M | Put options by funds: $28.3M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$21
91%
upside
Avg. target
$28
155%
upside
High target
$33
201%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Piper Sandler Biren Amin 15% 1-year accuracy 3 / 20 met price target | 91%upside $21 | Overweight Maintained | 14 Nov 2024 |
Stephens & Co. Sudan Loganathan 26% 1-year accuracy 5 / 19 met price target | 173%upside $30 | Overweight Initiated | 8 Nov 2024 |
Wedbush David Nierengarten 38% 1-year accuracy 49 / 128 met price target | 201%upside $33 | Outperform Reiterated | 25 Oct 2024 |
Financial journalist opinion
Based on 3 articles about IMNM published over the past 30 days
Positive
MarketBeat
1 week ago
3 Small-Cap Stocks With Big Growth Potential
According to several indicators—including a robust labor market and tamed inflation figures—the U.S. economy heads into 2025 with strong tailwinds. Many of the securities that have been primary beneficiaries of this economic well-being are large-cap (or even mega-cap) titans in the tech industry.
Neutral
Business Wire
2 weeks ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on December 2, 2024, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase 210,500 shares of common stock to 15 new employees under the Company's 2024 Inducement Plan. The.
Neutral
Business Wire
3 weeks ago
Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome's management will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024 at 4:30 p.m. Eastern time. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at ww.
Negative
Zacks Investment Research
1 month ago
Immunome, Inc. (IMNM) Reports Q3 Loss, Misses Revenue Estimates
Immunome, Inc. (IMNM) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.60. This compares to loss of $0.36 per share a year ago.
Neutral
Business Wire
1 month ago
Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update.
Neutral
Business Wire
1 month ago
Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Clay Siegall, PhD, President and CEO of Immunome, will participate in a fireside chat at Guggenheim's Inaugural Healthcare Innovation Conference on Wednesday, November 13th at 10:30am Eastern Time. Interested parties can access the live audio webcast for this conference from the Investor Relations section o.
Neutral
Business Wire
1 month ago
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on October 31, 2024, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase 378,800 shares of common stock to 14 new employees under the Company's 2024 Inducement Plan. The.
Neutral
Business Wire
1 month ago
Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, recently presented promising preclinical data for IM-1021 and the associated proprietary ADC payload HC74. The results were presented in a poster entitled “Preclinical evaluation of IM-1021, a ROR1-targeted antibody-drug conjugate with a novel topoisomerase I linker payload” at the 36th EORTC-NCI-AACR Symposium on Molecular Tar.
Neutral
Business Wire
2 months ago
Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it will present a poster highlighting preclinical evaluation of IM-1021, a ROR1-targeted antibody drug conjugate (ADC), at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Barcelona on October 24, 2024. Immunome expects to submit an IND for the IM-1021 program to the FDA in.
Neutral
Business Wire
2 months ago
Immunome Appoints Roee Shahar as Executive Vice President, Commercial
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on the development of first-in-class and best-in-class targeted oncology therapies, today announced the appointment of Roee Shahar as Executive Vice President, Commercial. Mr. Shahar brings over two decades of experience, including successfully launching and commercializing oncology and hematology products at Seagen, Pfizer (following the acquisition of Seagen in December 2023) and Eli Lilly & Co.
Charts implemented using Lightweight Charts™